{"id":202,"date":"2024-10-10T04:43:19","date_gmt":"2024-10-10T04:43:19","guid":{"rendered":"https:\/\/ixchiq.ca\/hcp\/?page_id=202"},"modified":"2026-05-05T05:12:56","modified_gmt":"2026-05-05T05:12:56","slug":"safety-profile","status":"publish","type":"page","link":"https:\/\/ixchiq.ca\/hcp\/safety-profile\/","title":{"rendered":"Safety profile"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"202\" class=\"elementor elementor-202\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4690d365 e-flex e-con-boxed e-con e-child\" data-id=\"4690d365\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-b656290 e-con-full e-flex e-con e-child\" data-id=\"b656290\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-1617d615 elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"1617d615\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-160cb119 elementor-widget elementor-widget-heading\" data-id=\"160cb119\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">IXCHIQ<sup>\u00ae<\/sup> DEMONSTRATED A GENERALLY WELL-TOLERATED SAFETY PROFILE<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-afd1d7d elementor-widget elementor-widget-text-editor\" data-id=\"afd1d7d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul class=\"list\">\n \t<li>In adults 18 years of age and older, the safety and tolerability profile of IXCHIQ<sup>\u00ae <\/sup>was evaluated in baseline seronegative adults in the study VLA1553-301.<sup>1<\/sup>*<\/li>\n \t<li>In adolescents aged 12 to 17 years, the safety and tolerability profile of IXCHIQ<sup>\u00ae <\/sup>was evaluated in a randomized, double-blind, placebo-controlled phase 3 trial.<sup>1\u2020<\/sup><\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-20d61c3 e-con-full e-flex e-con e-child\" data-id=\"20d61c3\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div class=\"elementor-element elementor-element-936ad79 e-con-full e-flex e-con e-child\" data-id=\"936ad79\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3d7cc92 elementor-widget elementor-widget-heading\" data-id=\"3d7cc92\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">THE FOLLOWING ARE THE MOST COMMON SOLICITED SYSTEMIC AND INJECTION SITE ADVERSE REACTIONS WITHIN 10 DAYS REPORTED IN ADULT AND ADOLESCENT SAFETY POPULATIONS.<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-88d4598 elementor-widget elementor-widget-image\" data-id=\"88d4598\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"931\" height=\"337\" src=\"https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2026\/04\/Infographic_Table_1_v2-1.png\" class=\"attachment-full size-full wp-image-4196\" alt=\"\" srcset=\"https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2026\/04\/Infographic_Table_1_v2-1.png 931w, https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2026\/04\/Infographic_Table_1_v2-1-300x109.png 300w, https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2026\/04\/Infographic_Table_1_v2-1-768x278.png 768w\" sizes=\"(max-width: 931px) 100vw, 931px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-cdc4636 elementor-widget__width-inherit elementor-widget elementor-widget-text-editor\" data-id=\"cdc4636\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tAdapted from the IXCHIQ\u00ae Product Monograph.<sup>1<\/sup>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f728832 elementor-widget elementor-widget-text-editor\" data-id=\"f728832\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul class=\"list\">\n \t<li>The majority of solicited systemic adverse reactions were of <strong>mild<\/strong> to <strong>moderate intensity <\/strong>(&gt;95% in adults; &gt;94% in baseline seronegative adolescents).<\/li>\n \t<li>In adults, the median day of onset was Day 2 after vaccination for local injection site adverse reactions and Day 5 after vaccination for systemic adverse reactions.<\/li>\n \t<li>Solicited systemic and local adverse reactions <strong>resolved with a median duration of <\/strong><strong>2 days in adults and\u00a01 to 2 days in baseline seronegative adolescents.<\/strong><\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-681b814 elementor-widget elementor-widget-heading\" data-id=\"681b814\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-heading-title elementor-size-default\"><div class=\"indent\"><span>* Studies (VLA1553-301, VLA1553-302, and VLA1553-101) all conducted in North America in healthy adult participants 18 years of age and older. Study VLA1553-101 was done using an earlier formulation and was a supportive <span class=\"inline\">dose-escalation<\/span> Phase I trial of IXCHIQ<sup>\u00ae<\/sup> in 120 participants. Study VLA1553-301 was the pivotal double-blind placebo-controlled Phase III trial in 4,115 participants who received IXCHIQ<sup>\u00ae<\/sup> or placebo (phosphate buffered saline) as a single dose. Study VLA1553-302 was a supportive non-placebo-controlled Phase III trial investigating the consistency of three lots of IXCHIQ<sup>\u00ae<\/sup> given as a single dose in 408 participants.<\/span><\/div>  <\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5906618 elementor-widget elementor-widget-heading\" data-id=\"5906618\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-heading-title elementor-size-default\"><div class=\"indent\"><span>\u2020 Study VLA1553-321 enrolled 754 participants who received either a single intramuscular dose (1\u00d710<sup>4 <\/sup>TCID<sub>50<\/sub>) of IXCHIQ<sup>\u00ae<\/sup> (n=502) or placebo (PBS; n=252), with a follow-up period of 6 months. 18.4% of participants had pre-existing antibodies against CHIKV, while 81.4% were CHIKV-na\u00efve. Randomization was stratified by CHIKV baseline serostatus.<\/span><\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-04f7555 e-con-full e-flex e-con e-parent\" data-id=\"04f7555\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-195291f elementor-widget elementor-widget-image\" data-id=\"195291f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"301\" height=\"301\" src=\"https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2024\/10\/Ixchic_Icon_people.jpg\" class=\"attachment-full size-full wp-image-1300\" alt=\"\" srcset=\"https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2024\/10\/Ixchic_Icon_people.jpg 301w, https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2024\/10\/Ixchic_Icon_people-150x150.jpg 150w\" sizes=\"(max-width: 301px) 100vw, 301px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5c2d3e2 e-flex e-con-boxed e-con e-parent\" data-id=\"5c2d3e2\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7fcf786 elementor-widget elementor-widget-heading\" data-id=\"7fcf786\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">FREQUENCY OF CHIKUNGUNYA-LIKE ADVERSE REACTIONS<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c9318d6 elementor-widget elementor-widget-text-editor\" data-id=\"c9318d6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tParticipants were monitored for a cluster of symptoms consistent with typical symptoms of wild-type chikungunya infection (chikungunya-like adverse reactions), defined as: \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c304cc2 elementor-widget elementor-widget-text-editor\" data-id=\"c304cc2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul class=\"list\">\n \t<li>fever (\u226538 \u00b0C in Study VLA1553-301 or \u226537.8 \u00b0C in Study VLA1553-321) and one or more of any of the following:<\/li>\n \t<li>arthralgia or arthritis, myalgia, headache, back pain (only in Study VLA1553-301), rash or certain skin symptoms, lymphadenopathy (only in Study VLA1553-301), or certain neurological, cardiac (only in Study VLA1553-301) or ocular symptoms that occurred with an onset within 30 days after vaccination, regardless of whether they occurred simultaneously or not.<\/li>\n \t<li>Severe chikungunya-like adverse reactions included symptoms that prevented daily activity and\/or required medical intervention.<\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-ac2a25e e-flex e-con-boxed e-con e-parent\" data-id=\"ac2a25e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-cf1c844 e-con-full e-flex e-con e-child\" data-id=\"cf1c844\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-815ccb2 elementor-widget elementor-widget-html\" data-id=\"815ccb2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<table class=\"frm_tbl\">\n<tr>\n<td>VLA1553-301 <br\/> <b>Adult participants (\u226518 years)<\/b><\/td>\n<td>VLA1553-321 <br\/> <b>Adolescent participants (12 to 17 years; baseline seronegative)<\/b><\/td>\n<\/tr>\n<tr>\n<td>11.7% in the IXCHIQ<sup>\u00ae<\/sup> group (n= 3082) reported chikungunya-like adverse reactions, including 1.6% who reported severe chikungunya-like adverse reactions. 0.6% participants in the placebo group (n=1033) reported chikungunya-like adverse reactions, none of which was severe.<br\/><br\/>The median onset of chikungunya-like adverse reactions in IXCHIQ<sup>\u00ae<\/sup> recipients was 3 days (range 0 to 10 days) after vaccination. The median duration of chikungunya-like reactions in IXCHIQ<sup>\u00ae<\/sup> recipients was 4 days (range 1 day to at least 6 months).<\/td>\n<td>27.0% in the IXCHIQ<sup>\u00ae<\/sup> group (n=408) reported chikungunya-like adverse reactions, including 4.2% who reported severe chikungunya-like adverse reactions. 3.9% baseline seronegative participants in the placebo group (n=206) reported chikungunya-like adverse reactions, none of which was severe.<\/td>\n<\/tr>\n<\/table>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-19763b2 elementor-widget elementor-widget-text-editor\" data-id=\"19763b2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tAdapted from the IXCHIQ\u00ae Product Monograph.<sup>1<\/sup>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-0fc88ee e-con-full e-flex e-con e-child\" data-id=\"0fc88ee\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-819aaaa elementor-widget elementor-widget-text-editor\" data-id=\"819aaaa\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div><strong><em>Adults &#8211; prolonged chikungunya-like adverse reactions<\/em><\/strong><\/div><div>22 IXCHIQ<sup>\u00ae<\/sup> recipients had prolonged chikungunya-like adverse reactions lasting longer than 14 days (median duration 33 days, range 15 days to at least 6 months).<\/div><div>15 IXCHIQ<sup>\u00ae<\/sup> recipients had chikungunya-like adverse reactions lasting longer than 28 days (median duration 94 days, range 29 days to at least 6 months).<\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-90df3ff elementor-widget elementor-widget-text-editor\" data-id=\"90df3ff\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div><strong><em>Baseline seronegative adolescents &#8211; prolonged chikungunya-like adverse reactions<\/em><\/strong><\/div>\n<div>15 IXCHIQ<sup>\u00ae<\/sup> recipients and 3 placebo recipients had prolonged chikungunya-like adverse reactions lasting longer than 14 days (median duration 23 days, range 16 to 30 days). <\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-47a32f5 e-flex e-con-boxed e-con e-parent\" data-id=\"47a32f5\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-a3b3b46 elementor-widget elementor-widget-heading\" data-id=\"a3b3b46\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">SERIOUS ADVERSE EVENTS<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4721db8 elementor-widget elementor-widget-heading\" data-id=\"4721db8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Adults<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-52153f6 elementor-widget elementor-widget-text-editor\" data-id=\"52153f6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul class=\"list\">\n \t<li>The proportions of participants who reported at least one serious adverse event within 6 months following administration was 1.5% (46\/3082) in the IXCHIQ\u00ae group and 0.8% (8\/1033) in the placebo group. Overall, there were two serious adverse events (2\/3082 [0.1%]) requiring hospitalization that were considered to be related to IXCHIQ\u00ae: 1 event of myalgia, and 1 event of hypovolemic hyponatremia and atrial fibrillation, both events showed full recovery. There were no serious adverse events reported in the placebo group.<\/li>\n<\/ul> \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5b7ba29 elementor-widget elementor-widget-heading\" data-id=\"5b7ba29\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Chikungunya virus baseline seronegative adolescents<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a95348d elementor-widget elementor-widget-text-editor\" data-id=\"a95348d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul class=\"list\">\n \t<li>The proportions of baseline seronegative participants who reported at least one serious adverse event within 6 months following administration was 1.2% (5\/408) in the IXCHIQ<sup>\u00ae<\/sup> arm and 1.0% (2\/206) in the placebo arm.<\/li>\n<\/ul> \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d722021 elementor-widget elementor-widget-heading\" data-id=\"d722021\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">DEATHS AND ADVERSE EVENTS LEADING TO WITHDRAWAL FROM STUDY<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-82ea665 elementor-widget elementor-widget-text-editor\" data-id=\"82ea665\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul class=\"list\">\n \t<li>Three participants died during Study VLA1553-301 due to events independent of study procedures (coronary artery disease, COVID-19, and anoxic brain injury). <strong>None of the deaths was considered as related to IXCHIQ\u00ae<\/strong>. Approximately 0.1% of participants who received IXCHIQ\u00ae vs. 0.2% in the placebo group discontinued their trial participation due to adverse events.<\/li>\n \t<li>No participants died during the adolescent study VLA1553-321 up to 6 months post vaccination.<\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-7d8701f e-con-full e-flex e-con e-parent\" data-id=\"7d8701f\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5b004ab elementor-widget elementor-widget-image\" data-id=\"5b004ab\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"301\" height=\"301\" src=\"https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2024\/10\/Ixchic_Icon_people.jpg\" class=\"attachment-full size-full wp-image-1300\" alt=\"\" srcset=\"https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2024\/10\/Ixchic_Icon_people.jpg 301w, https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2024\/10\/Ixchic_Icon_people-150x150.jpg 150w\" sizes=\"(max-width: 301px) 100vw, 301px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-f54c3b9 e-flex e-con-boxed e-con e-parent\" data-id=\"f54c3b9\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-a233468 elementor-widget elementor-widget-heading\" data-id=\"a233468\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">POST-MARKETING DATA  <\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-99aa6d0 elementor-widget elementor-widget-text-editor\" data-id=\"99aa6d0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul class=\"list\">\n \t<li>During post-marketing use, serious adverse reactions following vaccination with IXCHIQ\u00ae were most commonly reported in medically frail individuals with advanced chronic diseases, individuals at older age (i.e., \u226565 years of age, especially \u226575 years of age), and those with a high risk of having an undiagnosed immunocompromised condition <span class=\"inline\">(e.g., occult cancer<\/span> or immunosenescence).<\/li>\n \t<li><strong>Severe reactogenicity<\/strong> or <strong>chikungunya-like adverse reactions<\/strong> in medically frail individuals with chronic diseases may lead to deterioration of general condition including malaise and decreased appetite, exacerbation of preexisting diseases, confusional state, encephalopathy, or encephalitis, leading to falls, hospitalisation and death.<\/li>\n \t<li>During post-marketing, additional cases of <strong>prolonged chikungunya-like arthralgia<\/strong> occurred after vaccination with IXCHIQ\u00ae with a range of duration from <strong>a few weeks to <span class=\"inline\">&gt;5 months,<\/span><\/strong> with a few cases requiring follow-up with rheumatology.<\/li>\n \t<li><strong>Encephalitis and encephalopathy (including fatal outcomes)<\/strong> have been reported in individuals <strong>\u226574 years of age with multiple comorbidities<\/strong>.<\/li>\n \t<li>During the vaccine campaign to address an outbreak in R\u00e9union Island early in 2025, <strong>three deaths<\/strong> occurred within two weeks post-vaccination among <strong>frail elderly men with multiple comorbidities <\/strong>(advanced neurological disorders and respiratory illness, pneumonia), due to medical decompensation (88 and 77 years of age) or confirmed encephalitis (84 years of age); \u00a0<strong>one death<\/strong> was assessed as probably related to IXCHIQ\u00ae vaccination by the local health authority. <strong>No deaths were reported<\/strong> in individuals vaccinated for the purpose of international travel.<\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-af6d202 elementor-widget elementor-widget-text-editor\" data-id=\"af6d202\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<strong><em>Vaccinees should be instructed to promptly seek medical attention if they experience any of the above symptoms, suggestive of severe reactogenicity or severe <span class=\"inline\">chikungunya-like<\/span> adverse reactions, prolonged arthralgia, or neurological disorder after vaccination.<\/em><\/strong> \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-ea0e43e e-flex e-con-boxed e-con e-parent\" data-id=\"ea0e43e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-13c6a06 e-con-full e-flex e-con e-child\" data-id=\"13c6a06\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-40ffe67 elementor-widget elementor-widget-heading\" data-id=\"40ffe67\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-heading-title elementor-size-default\">POST-MARKET ADVERSE REACTIONS REPORTED WITHIN 30 DAYS OF RECEIVING IXCHIQ\u00ae<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0575495 elementor-widget elementor-widget-image\" data-id=\"0575495\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"1149\" height=\"1344\" src=\"https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2026\/04\/post-market-adverse-reactions-table.png\" class=\"attachment-full size-full wp-image-3666\" alt=\"\" srcset=\"https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2026\/04\/post-market-adverse-reactions-table.png 1149w, https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2026\/04\/post-market-adverse-reactions-table-256x300.png 256w, https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2026\/04\/post-market-adverse-reactions-table-875x1024.png 875w, https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2026\/04\/post-market-adverse-reactions-table-768x898.png 768w\" sizes=\"(max-width: 1149px) 100vw, 1149px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-6a8e89c e-flex e-con-boxed e-con e-parent\" data-id=\"6a8e89c\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-036bf2b elementor-widget elementor-widget-heading\" data-id=\"036bf2b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<p class=\"elementor-heading-title elementor-size-default\">For more information on clinical trial adverse reactions, please refer to the IXCHIQ\u00ae Product Monograph.<\/p>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-062c940 elementor-widget elementor-widget-heading\" data-id=\"062c940\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-heading-title elementor-size-default\"><div class=\"indent\"><span>* Safety data collected in 4,115 participants from the main VLA1553-301 clinical trial, randomized 3:1 to receive IXCHIQ<sup>\u00ae<\/sup> or PBS (placebo). A total of 3,082 healthy adults 18 through 88 years of age received a single intramuscular dose (1\u00d710<sup>4<\/sup> TCID<sub>50<\/sub>) of IXCHIQ<sup>\u00ae<\/sup> and 1,033 received placebo. Participants were followed-up for safety for 6 months post-vaccination.<\/span><\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1122330 elementor-widget elementor-widget-heading\" data-id=\"1122330\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-heading-title elementor-size-default\"><div class=\"indent\"><span>\u2020 Study VLA1553-321 enrolled 754 participants who received either a single intramuscular dose (1\u00d710<sup>4 <\/sup>TCID<sub>50<\/sub>) of IXCHIQ<sup>\u00ae<\/sup> (n=502) or placebo (PBS; n=252), with a follow-up period of 6 months. 18.4% of participants had pre-existing antibodies against CHIKV, while 81.4% were CHIKV-na\u00efve. Randomization was stratified by CHIKV baseline serostatus.<\/span><\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-10e40ee e-flex e-con-boxed e-con e-parent\" data-id=\"10e40ee\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3fdf311 elementor-align-right elementor-widget__width-inherit elementor-widget elementor-widget-button\" data-id=\"3fdf311\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/ixchiq.ca\/hcp\/dosing-reconstitution\/\" id=\"btn_2\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-chevron-right\"><\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">DOSING &amp; RECONSTITUTION<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>IXCHIQ\u00ae DEMONSTRATED A GENERALLY WELL-TOLERATED SAFETY PROFILE In adults 18 years of age and older, the safety and tolerability profile of IXCHIQ\u00ae was evaluated in baseline seronegative adults in the study VLA1553-301.1* In adolescents aged 12 to 17 years, the safety and tolerability profile of IXCHIQ\u00ae was evaluated in a randomized, double-blind, placebo-controlled phase 3 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-202","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Safety profile - Ixchiq HCP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ixchiq.ca\/hcp\/safety-profile\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Safety profile - Ixchiq HCP\" \/>\n<meta property=\"og:description\" content=\"IXCHIQ\u00ae DEMONSTRATED A GENERALLY WELL-TOLERATED SAFETY PROFILE In adults 18 years of age and older, the safety and tolerability profile of IXCHIQ\u00ae was evaluated in baseline seronegative adults in the study VLA1553-301.1* In adolescents aged 12 to 17 years, the safety and tolerability profile of IXCHIQ\u00ae was evaluated in a randomized, double-blind, placebo-controlled phase 3 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ixchiq.ca\/hcp\/safety-profile\/\" \/>\n<meta property=\"og:site_name\" content=\"Ixchiq HCP\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-05T05:12:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2024\/11\/info-table-2048x795-1.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/safety-profile\\\/\",\"url\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/safety-profile\\\/\",\"name\":\"Safety profile - Ixchiq HCP\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/safety-profile\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/safety-profile\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Infographic_Table_1_v2-1.png\",\"datePublished\":\"2024-10-10T04:43:19+00:00\",\"dateModified\":\"2026-05-05T05:12:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/safety-profile\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/safety-profile\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/safety-profile\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Infographic_Table_1_v2-1.png\",\"contentUrl\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Infographic_Table_1_v2-1.png\",\"width\":931,\"height\":337},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/safety-profile\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Safety profile\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/#website\",\"url\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/\",\"name\":\"Ixchiq HCP\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/#organization\",\"name\":\"Ixchiq HCP\",\"url\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/ixchiq-1.png\",\"contentUrl\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/ixchiq-1.png\",\"width\":500,\"height\":140,\"caption\":\"Ixchiq HCP\"},\"image\":{\"@id\":\"https:\\\/\\\/ixchiq.ca\\\/hcp\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Safety profile - Ixchiq HCP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ixchiq.ca\/hcp\/safety-profile\/","og_locale":"en_US","og_type":"article","og_title":"Safety profile - Ixchiq HCP","og_description":"IXCHIQ\u00ae DEMONSTRATED A GENERALLY WELL-TOLERATED SAFETY PROFILE In adults 18 years of age and older, the safety and tolerability profile of IXCHIQ\u00ae was evaluated in baseline seronegative adults in the study VLA1553-301.1* In adolescents aged 12 to 17 years, the safety and tolerability profile of IXCHIQ\u00ae was evaluated in a randomized, double-blind, placebo-controlled phase 3 [&hellip;]","og_url":"https:\/\/ixchiq.ca\/hcp\/safety-profile\/","og_site_name":"Ixchiq HCP","article_modified_time":"2026-05-05T05:12:56+00:00","og_image":[{"url":"https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2024\/11\/info-table-2048x795-1.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ixchiq.ca\/hcp\/safety-profile\/","url":"https:\/\/ixchiq.ca\/hcp\/safety-profile\/","name":"Safety profile - Ixchiq HCP","isPartOf":{"@id":"https:\/\/ixchiq.ca\/hcp\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ixchiq.ca\/hcp\/safety-profile\/#primaryimage"},"image":{"@id":"https:\/\/ixchiq.ca\/hcp\/safety-profile\/#primaryimage"},"thumbnailUrl":"https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2026\/04\/Infographic_Table_1_v2-1.png","datePublished":"2024-10-10T04:43:19+00:00","dateModified":"2026-05-05T05:12:56+00:00","breadcrumb":{"@id":"https:\/\/ixchiq.ca\/hcp\/safety-profile\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ixchiq.ca\/hcp\/safety-profile\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ixchiq.ca\/hcp\/safety-profile\/#primaryimage","url":"https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2026\/04\/Infographic_Table_1_v2-1.png","contentUrl":"https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2026\/04\/Infographic_Table_1_v2-1.png","width":931,"height":337},{"@type":"BreadcrumbList","@id":"https:\/\/ixchiq.ca\/hcp\/safety-profile\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ixchiq.ca\/hcp\/"},{"@type":"ListItem","position":2,"name":"Safety profile"}]},{"@type":"WebSite","@id":"https:\/\/ixchiq.ca\/hcp\/#website","url":"https:\/\/ixchiq.ca\/hcp\/","name":"Ixchiq HCP","description":"","publisher":{"@id":"https:\/\/ixchiq.ca\/hcp\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ixchiq.ca\/hcp\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ixchiq.ca\/hcp\/#organization","name":"Ixchiq HCP","url":"https:\/\/ixchiq.ca\/hcp\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ixchiq.ca\/hcp\/#\/schema\/logo\/image\/","url":"https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2024\/10\/ixchiq-1.png","contentUrl":"https:\/\/ixchiq.ca\/hcp\/wp-content\/uploads\/2024\/10\/ixchiq-1.png","width":500,"height":140,"caption":"Ixchiq HCP"},"image":{"@id":"https:\/\/ixchiq.ca\/hcp\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/ixchiq.ca\/hcp\/wp-json\/wp\/v2\/pages\/202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ixchiq.ca\/hcp\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ixchiq.ca\/hcp\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ixchiq.ca\/hcp\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ixchiq.ca\/hcp\/wp-json\/wp\/v2\/comments?post=202"}],"version-history":[{"count":152,"href":"https:\/\/ixchiq.ca\/hcp\/wp-json\/wp\/v2\/pages\/202\/revisions"}],"predecessor-version":[{"id":4452,"href":"https:\/\/ixchiq.ca\/hcp\/wp-json\/wp\/v2\/pages\/202\/revisions\/4452"}],"wp:attachment":[{"href":"https:\/\/ixchiq.ca\/hcp\/wp-json\/wp\/v2\/media?parent=202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}